Analysts think GUTS stock price could increase by 564%
May 15, 2025, 11:25 AM
41.37%
What does GUTS do
Fractyl Health, headquartered in Burlington, Massachusetts, focuses on treating metabolic diseases like type 2 diabetes and obesity with its Revita DMR System and Rejuva gene therapy. The company went public on February 2, 2024, and employs 102 full-time staff.
5 analysts think GUTS stock price will increase by 564.50%. The current median analyst target is $10.20 compared to a current stock price of $1.53. The lowest analysts target is $6.06 and the highest analyst target is $12.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
